Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Liabilities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Total Liabilities for 4 consecutive years, with $697.3 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 10.35% to $697.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $697.3 million through Dec 2025, up 10.35% year-over-year, with the annual reading at $697.3 million for FY2025, 10.35% up from the prior year.
  • Total Liabilities for Q4 2025 was $697.3 million at Phathom Pharmaceuticals, up from $662.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $697.3 million in Q4 2025, with the low at $111.0 million in Q1 2022.
  • Average Total Liabilities over 4 years is $433.5 million, with a median of $495.8 million recorded in 2023.
  • The sharpest move saw Total Liabilities soared 125.37% in 2024, then rose 10.35% in 2025.
  • Over 4 years, Total Liabilities stood at $239.6 million in 2022, then soared by 103.07% to $486.6 million in 2023, then grew by 29.86% to $631.9 million in 2024, then grew by 10.35% to $697.3 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $697.3 million, $662.8 million, and $656.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.